Tiger Brokers

UltraGreen.ai's Latest Approvals Lay Groundwork for Future Expansion -- Market Talk

Dow Jones
Mar 13

0647 GMT - Regulatory approvals for UltraGreen.ai's fluorescence imaging system in new markets lays the groundwork for future Asia-Pacific expansion, says DBS Group Research's Amanda Tan in a note. The approvals strengthen Ultragreen's ability to work with healthcare institutions and distribution partners, the analyst notes. However, not all required components, such as the dye needed for surgeries, have been approved, and she doesn't expect the healthcare-technology company to immediately enter these markets. Its Asia-Pacific revenue therefore isn't likely to be materially accretive in the near term, with earnings uplift likely to be progressive, she says. DBS maintains its buy rating and US$2.00 target price. Shares rise 0.65% to US$1.55. (megan.cheah@wsj.com)

(END) Dow Jones Newswires

March 13, 2026 02:47 ET (06:47 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10